WuXi AppTec Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on WuXi AppTec Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how WuXi AppTec Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with WuXi AppTec Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
WuXi AppTec Co Ltd (WuXi AppTec) is a pharmaceutical company that provides research and development and manufacturing services. The company offers biology services, including hit finding, integrated drug discovery, discovery biology, analytical services, and oncology services. Its small molecule (contract research, development, and manufacturing organization CRDMO) services include research chemistry services and development and manufacturing services. WuXi AppTec’s drug research and development testing caters to safety assessment services, bioanalytical services, and DMPK services. The company’s clinical research services include medical affairs, regulatory affairs and quality system management and consulting services. It provides services through its integrated end to end contract research, development, and manufacturing organization platform. The company serves pharmaceutical, biotech and medical device industries. WuXi AppTec is headquartered in Shanghai, China.
Headquarters
China
Address
288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, 214092
Website
www.wuxiapptec.com
Telephone
86 21 50461111
No of Employees
33,834
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
603259 (SHA)
Revenue (2024)
$6.3B
15.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
102.6%
(2024 vs 2023)
Market Cap*
$54.9B
Net Profit Margin (2024)
XYZ
75.0%
(2024 vs 2023)
* As of and is in US$
WuXi AppTec Co Ltd premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Plaftform: | Biology: |
| Contract Research, Development, and Manufacturing Organization (CRDMO) platform | Integrated Drug Discovery |
| Hit Finding | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In November, the company partnered with European scientific institutions, venture capital networks, and biotech startups to speed up the translation of discoveries into impactful healthcare solutions. |
| 2025 | Contracts/Agreements | In October, the company signed a memoranda of understanding with NEOM and the Ministry of Health of the Kingdom of Saudi Arabia to explore the localization of pharmaceutical research, development and manufacturing in Saudi Arabia. |
| 2025 | Divestiture | In March, the company sold its US medical device testing operations to NAMSA, a contract research organization. |
Competitor Comparison
| Key Parameters | WuXi AppTec Co Ltd | Thermo Fisher Scientific Inc | Pharmaron Beijing Co Ltd | Hangzhou Tigermed Consulting Co Ltd | JOINN Laboratories China Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | United States of America | China | China | China |
| City | Shanghai | Waltham | Beijing | Hangzhou | Beijing |
| State/Province | Shanghai | Massachusetts | Beijing | Zhejiang | Beijing |
| No. of Employees | 33,834 | 125,000 | 25,088 | 11,130 | 2,649 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Zhang Zhaohui | Chief Operating Officer; Vice President; Director | Executive Board | 2017 | 56 |
| Ge Li | Chairman; Chief Executive Officer; President | Executive Board | 2023 | 58 |
| Mingzhang Chen | Co- Chief Executive Officer; Director | Executive Board | 2022 | 56 |
| Steve Qing Yang | Co- Chief Executive Officer; Director | Executive Board | - | - |
| Shi Ming | Chief Financial Officer | Senior Management | 2022 | 51 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer